Mendus AB (publ)
IMMU.ST - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$355.51M
Close$
$0.88
83.6% downside
Current Fair Value
83.6% downsideOvervalued by 83.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $355.51 Million |
|---|---|
| Enterprise Value | $313.55 Million |
| Earnings per Share | $-2.17 |
| Beta | 0.76 |
| Outstanding Shares | 62,873,529 |
Return
| Return on Equity | -18.80% |
|---|---|
| Return on Assets | -16.49% |
| Return on Invested Capital | -20.09% |
Valuation & Multiples
| P/E Ratio | -3.13 |
|---|---|
| PEG | 54.22 |
| Price to Sales | - |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.78 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.44
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.48
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Mendus AB (publ)
19 employees
CEO: Erik Manting
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigatio...